Varma Mutual Pension Insurance Co Has $22.71 Million Stock Position in Gilead Sciences, Inc. $GILD

Varma Mutual Pension Insurance Co raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 204,615 shares of the biopharmaceutical company’s stock after purchasing an additional 16,800 shares during the quarter. Varma Mutual Pension Insurance Co’s holdings in Gilead Sciences were worth $22,712,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Csenge Advisory Group raised its position in shares of Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after acquiring an additional 16,288 shares during the last quarter. Railway Pension Investments Ltd increased its position in Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after purchasing an additional 42,200 shares during the period. TriaGen Wealth Management LLC bought a new position in Gilead Sciences during the 3rd quarter worth approximately $1,274,000. iA Global Asset Management Inc. raised its holdings in Gilead Sciences by 11.6% during the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after purchasing an additional 23,046 shares during the last quarter. Finally, Sector Gamma AS lifted its position in shares of Gilead Sciences by 15.9% in the 3rd quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock worth $16,344,000 after purchasing an additional 20,239 shares during the period. 83.67% of the stock is owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 beat on top and bottom line: Gilead reported Q4 EPS of $1.86 vs. consensus ~$1.83 and revenue roughly $7.9B, powered by HIV and liver‑disease franchises — the core beat is the primary near‑term driver of the rally. Gilead quarterly results beat Wall Street estimates
• Positive Sentiment: Multiple analyst upgrades/price‑target raises: Banks including Morgan Stanley, JPMorgan, Wells Fargo, Needham and others bumped targets (some to $160–$177+), reinforcing buy/overweight sentiment and supporting the stock pop. Morgan Stanley raises price target
• Positive Sentiment: Yescarta label expansion and pipeline momentum: Positive commentary about CAR‑T (Yescarta) label expansion and new HIV options (Yeztugo) adds optionality to growth expectations. Yescarta label expansion and dividend growth
• Positive Sentiment: Dividend increase: Board raised the quarterly payout to $0.82 (3.8% increase), supporting income investors and reducing equity downside for dividend‑focused holders. Dividend announcement
• Neutral Sentiment: Investor commentary and transcripts: Earnings call and slides are available for detail on unit trends and margin commentary — useful for modeling but not an immediate directional driver. Earnings call transcript
• Neutral Sentiment: Short‑interest items in recent filings show no meaningful or reliable signal (reported zero/odd values), so ignore those as noise.
• Negative Sentiment: FY‑2026 guidance came in slightly light: Gilead set EPS guidance of $8.45–$8.85 and revenue guidance ~$29.6–$30.0B, marginally below consensus (~$30.1B / ~$8.69 EPS), which caused an initial after‑hours pullback and remains the main near‑term risk to sustaining the rally. Guidance story
• Negative Sentiment: Some cautious analyst views remain: A few firms (e.g., RBC with a lower PT) kept conservative ratings/targets, which could cap upside if other brokers re‑rate lower or fundamentals disappoint. Analyst notes (RBC)

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at $1,115,713.60. This represents a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 319,391 shares of company stock valued at $44,141,101 over the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on GILD shares. Truist Financial increased their price objective on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Wednesday. Daiwa Securities Group upped their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Citigroup boosted their price objective on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Finally, Argus boosted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Twenty-four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $146.44.

Gilead Sciences Stock Up 5.8%

Shares of NASDAQ:GILD opened at $155.80 on Thursday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The business’s 50 day simple moving average is $129.01 and its two-hundred day simple moving average is $121.77. The firm has a market cap of $193.30 billion, a P/E ratio of 23.01, a PEG ratio of 0.78 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 51.04% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the previous year, the company posted $1.90 earnings per share. The company’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.1%. Gilead Sciences’s dividend payout ratio is currently 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.